Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships
The aims were (1) to evaluate the molecular weight (MW) dependence of biliary excretion and (2) to develop quantitative structure–pharmacokinetic relationships (QSPKR) to predict biliary clearance (CLb) and percentage of administered dose excreted in bile as parent drug (PDb) in rats and humans. CLb and PDb data were collected from the literature for rats and humans. Receiver operating characteristic curve analysis was utilized to determine whether a MW threshold exists for PDb. Stepwise multiple linear regression (MLR) was used to derive QSPKR models. The predictive performance of the models was evaluated by internal validation using the leave-one-out method and external test groups. A MW threshold of 400 Da was determined for PDb for anions in rats, while 475 Da was the cutoff for anions in humans. MW thresholds were not present for cations or cations/neutral compounds in either rats or humans. The QSPKR model for human CLb showed a significant correlation (R 2 = 0.819) with good prediction performance (Q 2 = 0.722). The model was further assessed using a test group, yielding a geometric mean fold-error of 2.68. QSPKR models with significant correlation and good predictability were also developed for CLb in rats and PDb data for anions or cation/neutral compounds in rats and humans. Both CLb and PDb data were further evaluated for subsets of MRP2 or P-glycoprotein substrates, and significant relationships were derived. QSPKR models were successfully developed for biliary excretion of non-congeneric compounds in rats and humans, providing a quantitative prediction of biliary clearance of compounds.
Key wordsbiliary clearance humans in silico molecular weight cutoff molecular volume QSPKR rats
Breast cancer resistance protein
Multidrug resistance-associated protein 2
% of dose eliminated in the bile as parent drug
Quantitative structure pharmacokinetic relationship
This work was supported in part by Pfizer Inc. We thank Dr. Lisa J. Benincosa from the Groton/New London Laboratories at Pfizer Inc. for her support and suggestions regarding this research. We thank Dr. Xueya Cai from Division of Biostatistics of Indiana University for her help with receiver operating characteristic curves analysis.
- 4.Millburn P. Factors in the Biliary Excretion of Organic Compounds. In: Fishmen W, editor. Metabolic conjugation and metabolic hydrolysis. New York: Academic; 1970. p. 1–74.Google Scholar
- 9.Hubbard RS, Butsch WL. Concentration of free sulfanilamide, sulfapyridine and sulfathiazol in material drained from human biliary tract. Proc Soc Exp Biol Med. 1941;46:484–487.Google Scholar
- 19.Ng C, Xiao Y, Putnam W, Lum B, Tropsha A. Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods. J Pharm Sci. 2004;93:2535–44.PubMedCrossRefGoogle Scholar
- 29.Draper NH, Smith H. Applied regression analysis. 3rd ed. Hoboken: Wiley; 1998.Google Scholar
- 43.Smith DA, van de Waterbeemd H, Walker DK, Mannhold R, Kubinyi H, Timmerman H. Pharmacokinetics and metabolism in drug design. Weinheim: Wiley; 2001. p. 59–66.Google Scholar
- 45.Smith RL. The excretory function of bile. London: Chapman & Hall; 1973. p. 16–34.Google Scholar